Introduction
The overweight and obese population both in the United States (US) and globally has increased over several decades. For example, in the US, 68% of adults are overweight or obese. 1 The consequent rise in associated diseases such as type 2 diabetes, cardiovascular diseases, and some cancers 2,3 is a major public health concern. It is estimated that health care costs attributable to overweight and obesity will double every decade, reaching 860.7 to 956.9 billion US dollars and accounting for 16-18% of total US health care costs by 2030. 4 Body weight is influenced by the interaction of biological, environmental, and physiological factors. A number of hormonal, neuronal, and metabolic responses that orchestrate this process are located in the gut. [5] [6] [7] Thus, the gastrointestinal (GI) tract plays a pivotal role in regulating food intake. The ileal brake is a negative feedback mechanism that is activated by the entry of nutrients into the ileum. 8 The inhibitory effects of the activation of the ileal brake are a result of the interaction of neural and humoral signals 9 exerting their influence on the proximal parts of the intestine. Exposure of the ileum to fats and fatty acids delays gastric emptying, 10, 11 prolongs GI transit time, 12 and influences satiety. [13] [14] [15] The physicochemical properties of fat affect its ability to regulate GI motor function, gut hormone release, and satiety. These effects are more pronounced with long chain fatty acids (≥12 carbons) than with shorter chain fatty acids (≤10 carbons). 16, 17 There is also growing evidence that free fatty acids are stronger mediators of the GI effects of fat than triacylglycerides. 18 The role played by the degree of saturation in modulating the effects of fat on the GI tract has not been resolved fully. 19, 20 Delaying lipid digestion is an important factor in stimula-ting the ileal brake. By manipulating oil emulsions using galactolipids, lipolysis can be delayed through the inhibition of lipase activity. 21 Olibra™ (Lipid Technologies Provider AB, Karishamn, Sweden) is a fat emulsion composed of fractionated palm and oat oil in the proportion of 95:5. The palm oil is emulsified by hydrophilic galactolipids derived from oat oil. 22 Olibra has been demonstrated in some studies to increase satiety and reduce food intake. [23] [24] [25] Other studies, however, have not replicated these effects on food intake 26, 27 although a positive effect on maintenance of weight loss 28 and fat loss 28, 29 have been demonstrated. Randomized, clinical weight-loss trials have not been reported. Studies that employed methods of delivering the emulsion directly into the GI tract have demonstrated a delay in GI transit. 22, 30 However, when ingested orally, this fat emulsion may not elicit the GI responses manifested by an intragastric or intraduodenal administration. In the dynamic environment of the GI tract, resistance of the emulsion to digestion is crucial for stimulating an increase in satiety and a reduction in food intake.
The purpose of this study was to determine whether Olibra in conjunction with a healthy diet and exercise plan would result in weight loss that was associated with a reduction in food intake. The incidence of adverse effects of Olibra administration was also evaluated.
Methods

Subjects
Subjects of both sexes 18-60 years of age with a body mass index (BMI) between 25 and 40 kg/m 2 , inclusive, were recruited from the communities surrounding the Pennington Biomedical Research Center (PBRC) in Baton Rouge, Louisiana. Subjects were eligible for the trial if they were determined to be healthy at a physical exam and had clinically normal findings in laboratory measurements. Questionnaires related to dietary restraint, 31 sandwich rating (to ensure that food used in the study was not disliked), and food selection 32 were completed. All subjects completed a 6-n-propylthiouracil (PROP) 33 test to determine if they were nontasters, medium tasters, or supertasters. Exclusion criteria included (1) a dietary restraint score of >13, (2) weight loss ≥4.5 kg in the preceding 3 months, (3) a medical condition or taking regular medication, (4) history of alcohol or other drug abuse in the preceding 1 year, and (5) pregnancy, lactation, or postpartum less than 6 months.
The study was approved by the Institutional Review Board of the PBRC, and participants provided written informed consent. The trial was registered on ClinicalTrials.gov under NCT01416051.
Study Design
The study followed a two-phased, randomized, placebocontrolled, double-blind, parallel design.
Phase I
At visit 1 (day -7 ± 2), qualified subjects arrived at the PBRC in the morning after a 12-hour overnight fast. Vital signs and weight were measured. Subjects were asked to consume an entire 382 kilocalorie (kcal) breakfast consisting of a serving of yogurt containing placebo (milk fat) followed by a cereal bar. Subjects returned 4 h later for a lunch meal consisting of a serving of yogurt containing placebo followed by more sandwiches, chips, and cookies than could reasonably be consumed. They returned 5 h later for a buffet dinner meal. The food intake at lunch and dinner was determined by subtracting the weight of the uneaten food from its original weight. The kcal and macronutrient intakes were calculated using product information and the United States Department of Agriculture (USDA) nutrient database. 34 Subjective ratings (appetite and satiety) were recorded through visual analog scales (VASs). Concomitant medications and any adverse events were assessed throughout the entire study to determine the feasibility of subjects' continuance with the study. One week later, at visit 2 (day 0 ± 2), the subjects arrived at the PBRC in the morning after a 12 h overnight fast and were randomized to the Olibra or placebo group. Vital signs, weight, waist and hip circumferences, and body fat measurements were taken. The food intake test conducted at visit 1 was repeated, except that subjects were given the yogurt with Olibra or the placebo added to it at breakfast and lunch.
Phase II
After the food intake test at visit 2, subjects were instructed by a registered dietitian to follow a 1500-kcal diet and encouraged to increase their current activity level. Olibra or the placebo was dispensed in a double-blind manner in ready-to-use portion packs. The subjects were instructed to consume the product twice daily, preferably with breakfast and lunch, for 12 weeks. Vital signs and weight measurements followed at visits 3-6 [days 14, 28, 56, and 84 (± 2)]. Subjects were considered compliant if they consumed the recommended dose at least 70% of the time. At visit 4, subjects repeated the food intake testing protocol followed at visit 2. At visit 6 (day 84 ± 2), subjects arrived at the PBRC after a 12 h overnight fast. Body fat, and waist and hip circumferences were measured. Blood tests and the physical exam performed at screening were repeated at visit 6. A schedule of assessments is presented in Table 1 .
Test Products
One serving of the test product was 7.5 g (19 kcal), providing 2.1 g of the fat emulsion Olibra. One serving of the placebo was also approximately 7.5 g (18.5 kcal), providing 1.95 g of 100% milk fat and small amounts of carbohydrate (0.2 g) and protein (0.3 g). At the food intake tests, Olibra or the placebo was added to a 200 g carton of fruit-flavored yogurt-194 kcal, 1.8 g fat, 38.6 g carbohydrate, and 5.8 g protein.
Measurements
Anthropometry Body weight was measured 35 at all visits. Fasting measurements were taken at screening and at visits 1, 2, 4, and 6. Height was measured 35 at screening to determine BMI [weight (kg)/height squared (m 2 )]. Waist and hip circumferences were measured 35 and the waist-hip ratio was calculated. 36 Body composition was measured using bioelectrical impedance (RJL Systems, BIA101A, Clinton Township, MI).
Questionnaires
Each food intake test was preceded by a questionnaire about colds or allergies that might affect taste. Eating Inventory (EI) 31 was administered at screening and prior to the food intake test on day 28. The food intake tests were accompanied by VASs administered before and after breakfast, lunch, and dinner. Participants rated their degree of each subjective state by placing a hash mark on a 100-mm line. The 100-mm line was anchored using the descriptors "Not at all" to "Extremely." Hunger, fullness, desire to eat, food craving, desire for sweet, desire for salty, and desire for fatty foods were assessed. Visual analog scales were also used to assess hedonic (sensory) responses to the yogurt served at breakfast and lunch on all food-intake test days. The Food Selection Questionnaire 32 was used to rate the participants' food preferences from a wide variety of foods that were offered at the buffet dinner meals.
Adverse Events
An adverse event was defined as any adverse change from baseline (pretreatment) condition that occurred during the course of the study after treatment had started, whether considered related to treatment or not. All adverse events, including intercurrent illnesses and an increase in severity or frequency of a concomitant sign/symptom of a concomitant illness, were documented.
Statistical Analysis
The food intake testing reported in the literature suggests that Olibra will reduce food intake by 20-30%. [23] [24] [25] From past experience, one can detect a 12% decrease in food intake in the eating laboratory with 30 subjects as their own controls. 37 The difference in food intake decreases with time on a diet. 37 Therefore, 82 subjects were randomized in this study. This allowed for 30 subjects per group to complete week 4 of the study assuming 30% maximum attrition. Assuming a standard deviation of 2.3 kg and an alpha of 0.05, the study was powered at 89% to detect a difference of 2 kg in weight loss between the groups at 12 weeks if 28 subjects finished per group.
Observations made during visit 1 of the study were considered as baseline measurements. A repeated measures analysis of covariance (ANCOVA) with baseline covariates was used to test if change in energy intake from baseline to week 4 differed significantly between the test and control groups. Body weight, waist circumference, waisthip ratio, percent body fat, and EI scores were analyzed similarly. The changes from baseline for the scores for appetite and satiety assessed through VASs were analyzed by doubly repeated measures ANCOVA. Visual analog scales used to assess hedonic responses to the test and control yogurt were analyzed directly rather than as change scores in a repeated measures analysis of variance. Chi-square test was used to analyze the distribution of tasters. Food intake and body weight were analyzed by stratifying taster status. Post hoc tests when conducted followed the Tukey-Kramer adjustment. All analyses were carried out using SAS (v. 9.2; SAS Institute, Inc., Cary, NC). Subject characteristics are presented as mean ± standard deviation (SD) and efficacy endpoints are presented as mean ± standard error of the mean (SEM). 
Results
Data related to 71 subjects were analyzed, and 57 subjects completed the study (Figure 1 ). Descriptive characteristics of the subjects at baseline are summarized in Table 2 .
Anthropometry
At the end of 12 weeks, body weight was significantly reduced in both groups (test group: 2.17 ± 0.46 kg, p < .0001) (control group: 1.68 ± 0.42 kg, p < .0001) with no significant difference between groups ( Table 3) . Waist circumference decreased by 2.93 ± 0.85 cm in the test group (p = .001) and by 1.78 ± 0.74 cm in the control group (p = .02), with no significant difference between the two treatment regimens. The waist-hip ratio decrease by 0.014 ± 0.007 in the test group and by 0.012 ± 0.006 in the control group was not significant, with no statistical difference between the groups. Neither group experienced a significant change in percent body fat or lean tissue as assessed by bioelectrical impedance.
Food and Energy Intake
There were no significant differences in the mean energy, Waist-hip ratio 0.9 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 .7 
Waist (cm) macronutrient, or amount of food consumed in the test group when compared with the control group ( Table 4) . Based on within-group analyses, on day 0, there was no significant change in the energy, macronutrient, or amount of food consumed in the test group as compared with their intake on day -7. The results were similar for the lunch, dinner, and total (lunch + dinner) meal intake.
Subjective Ratings
No significant treatment effects were found for any of the appetite and satiety measures over the various time periods. There was no significant difference in VAS ratings of pleasantness, palatability, desirability, and capacity to satiate between the test and control yogurt served at the food intake tests.
Adverse Events
Fifty-eight adverse events were reported (test group: 26, control group: 32). Forty adverse events were resolved (test group: 20, control group: 20). There were 18 adverse events ongoing at the end of the study. Six were reported in the test group and 12 in the control group (Table 5) . There were no serious adverse events (life threatening, requiring hospitalization, or significantly disabling).
6-n-propylthiouracil Test
There were 24.2% supertasters, 57.6% medium tasters, and 18.2% nontasters in the test group as compared with 21.6% supertasters, 62.2% medium tasters, and 16.2% nontasters in the control group. Taster status did not indicate a differential response to food intake or an influence on body weight.
Eating Inventory
There were no significant changes in the scores for dietary restraint and disinhibition, however, hunger scores were significantly reduced in the test group as compared with the control group (p = .0082) (Figure 2 ). 
Discussion
At the end of 12 weeks, a reduction in body weight and waist circumference did occur but the differential reduction was not statistically significant between the groups. Eating Inventory scores for hunger, which reflect an individual's perception of hunger feelings, were significantly reduced in the test group as compared with the control group, however, no significant treatment effects were observed on energy intake, food intake, and appetite and satiety ratings after 4 weeks of Olibra consumption.
Earlier studies, [23] [24] [25] all crossover designs, reported a reduction in energy, macronutrient, and total weight of food intake following consumption of the Olibra emulsion. The suppressive effects on appetite ratings (hunger, desire to eat, and preoccupation with thoughts of food or perceived fullness) in the short term were only demonstrated in one study 24 and one part of another. 23 In the present study, there was no significant reduction in energy, macronutrient, or total weight of food intake 4 or 9 h after consumption of Olibra based on within-and betweengroup analyses. Crossover designs minimize the errors of individual variability, hence the present study was designed to evaluate the acute effects of Olibra using a within-subject analysis in addition to its effects on two different groups. Using self-reported food intake data, Burns and colleagues 25 concluded that the treatment effects of Olibra were maintained up to 36 hours. However, self-reported data are notorious for their susceptibility to misreporting and altered feeding behavior.
Two subsequent studies failed to confirm the reduction in energy intake 26, 27 although a suppressive effect on appetite ratings (hunger, fullness, desire to eat, and prospective intake or preoccupation with thoughts of food) was demonstrated. 27 No effect on body weight, body composition, or waist circumference was observed after 3-weeks' consumption of Olibra. 26 A meta-analysis 38 of the short-term effects of Olibra on food intake attributed the differences in findings partly to the manufacture, processing, or preparation of Olibra. It has been speculated that the functional integrity of the Olibra emulsion structure is affected when it is subjected to processing such as homogenization and pasteurization along with the yogurt. The emulsion used in the present study was added after the yogurt, served at the food intake tests, was manufactured. It was therefore not subjected to further processing. The demonstrated efficacy of unprocessed as compared with processed Olibra in reducing energy and food intake 39 at 8 h was not observed. However, these investigators also found no effects on hunger, fullness, and satiety.
All of the studies that investigated the effects of oral ingestion of Olibra used between 4 and 5 g of the emulsion except for one study 25 that investigated the dose response using 2, 4, and 6 g and found no difference between the doses. Eating behavior is composed of a large learned and anticipatory component. 40 Behavioral and environmental factors can overcome physiological drives and influence feeding behavior. 41 Therefore, a physiological impetus would have to be sufficiently large to consistently correlate with altered energy and nutrient intakes. Additionally, the relatively small sample sizes used in all the studies resulted in divergent results since the actual difference was much smaller than the expected difference.
The beneficial effects of Olibra on body composition and weight maintenance after weight loss have been demonstrated, 28 however, Olsson and colleagues 29 observed no effect on weight although body fat mass decreased after an initial weight loss period. In these studies, the calorie restriction imposed during the weight loss period may have had a role to play in the demonstrated effects. In humans, it has been shown that exposure to a high-fat or high-energy diet decreases sensitivity to the GI mechanisms involved in appetite regulation. 18, 42, 43 High-fat diets have been shown to modify appetite perceptions, increasing hunger and decreasing fullness. 44 If the subjects in the present study usually consumed a high-fat or high-calorie diet, the effect of Olibra could have been attenuated. Nevertheless, the ultimate goal of altering appetite and satiety signals is to correct energy imbalance and reduce weight, which as demonstrated in this study, was far from accomplished with the consumption of Olibra.
A 45-minute delay in intestinal transit time following consumption of Fabuless (also known as Olibra) has been reported 30 but the computation of orocecal transit time has been questioned. 41 Using an intragastric administration technique to infuse Fabuless, Knutson and colleagues 22 concluded that the palmitic acid crystals observed in the jejunal samples of subjects caused a reduction in intestinal digestion and absorption rates. Both studies used a single dose of 8.5 g of Olibra to produce these effects, which is about twice the daily dose used in the present study. While it is important to demonstrate that Olibra produces conditions conducive to stimulation of the ileal brake mechanism, such manipulation must also produce the directional changes in feeding behavior consistent with the activation of this mechanism.
The present study is limited by the nonavailability of information related to subjects' usual intake, to determine if earlier patterns of nutrient exposure were related to the results of the study. A review of published human studies that investigated the effects of Olibra is presented in Table 6 .
Conclusion
The Olibra emulsion had no significant effect on food intake, appetite and satiety ratings, body weight, or body composition. The results of studies indicating the beneficial effects of Olibra have not been confirmed in separate studies. A review of the available evidence indicates that further investigation of Olibra as a means of regulating appetite, satiety, food intake, and thereby body weight is not warranted. 
